Sanofi has entered an agreement to acquire Vigil Neuroscience for approximately USD 470 million, securing rights to VG-3927, an oral TREM2-targeting small molecule agonist preparing for Phase II trials in Alzheimer's disease. The deal includes contingent value rights potentially worth USD 2 per share upon first commercial sale. Vigil's pipeline also includes the TREM2 monoclonal antibody VGL101, though this asset remains outside the acquisition.

Meanwhile, Eli Lilly will acquire SiteOne Therapeutics for up to USD 1 billion, gaining STC-004, a Nav1.8 inhibitor positioned as a next-generation non-opioid pain therapy entering Phase II development. The acquisition follows SiteOne's USD 100 million Series C financing in December 2024 and strengthens Lilly's neuroscience portfolio with a promising alternative to existing pain treatments.